Home > Oncology > WCLC 2018 > New Aspects of Immunotherapy > Next generation immunotherapy in non-small-cell lung cancer

Next generation immunotherapy in non-small-cell lung cancer

Presented By
Prof. Solange Peters, Lausanne University Hospital and Ludwig Institute, Switzerland
Conference
WCLC 2018
Immunotherapy is a game-changer in cancer research and treatment. For the first time in decades, its use has led to new standards of care in at least three refractory lung cancers: stage 3 unresectable non-small-cell lung cancer (NSCLC; PACIFIC), extensive-stage small-cell lung cancer (IMpower133), and squamous NSCLC (KEYNOTE-407). Research is rapidly expanding our knowledge of the immune system and how it interacts with cancer cells. While much work remains to be done, progress is accelerating. Future advances will feature new biomarkers and agents as well as new strategic directions, such as "immune normalisationā€ [1]. Prof. Solange Peters (Lausanne University Hospital and Ludwig Institute, Switzerland) described immunotherapy as a revolution in cancer care. ā€œOver 2000 immunotherapy agents are in development,ā€ she said at the Future of IO, a mini-symposium on immuno-oncology. She showed how phenotypes in the immune cycle are affected by inflamed tumour...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on